Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy

BACKGROUND: The CAR T-cell therapy is a promising approach to treating hematologic malignancies. However, the application in solid tumors still has many tough challenges, including heterogenicity in antigen expressions and immunosuppressive tumor microenvironment (TME). As a new cancer treatment mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuanyuan, Zheng, Yanxin, Deng, Tianyi, Huang, Yue, Liu, Ziwen, Zhan, Borui, Zhou, Xusha, Yan, Runbin, Ren, Jiangtao, Xing, Yun, Wu, Guixing, Zheng, Biao, Hu, Guang, Wang, Wen, Liu, Yonghong, Zhao, Jing, Chen, Xiaoqing, Zhou, Grace Guoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638445/
https://www.ncbi.nlm.nih.gov/pubmed/36353540
http://dx.doi.org/10.3389/fonc.2022.1037934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638445/
https://www.ncbi.nlm.nih.gov/pubmed/36353540
http://dx.doi.org/10.3389/fonc.2022.1037934

Ejemplares similares